Čájehuvvojit 1 - 6 oktiibuot 6 bohtosis ohcui Sushil Kumar (20371917)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells

    Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplementary Figure 1: Activation of AD-MSCs and PSCs by Muc5ac

    Supplementary Figure 1: Activation of AD-MSCs and PSCs by Muc5ac Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Supplementary Figure 4: RNA-sequencing in the primary AD-MSCs, BM-MSCs, and PSCs after treatment with KC and KCM serum

    Supplementary Figure 4: RNA-sequencing in the primary AD-MSCs, BM-MSCs, and PSCs after treatment with KC and KCM serum Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Supplementary Tables

    Supplementary Tables Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Supplementary Figure 6: Age-dependent differences in CAF activation

    Supplementary Figure 6: Age-dependent differences in CAF activation Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac

    Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac Dahkki Sushil Kumar (20371917)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: